Continuing Education Activity

Isoproterenol, also known as isoprenaline, is a nonselective beta-1 and beta-2 adrenergic receptor agonist primarily used in the management of bradydysrhythmias and for electrophysiologic evaluation in supervised clinical settings. The administration and postadministration monitoring of this drug are complex and require a coordinated interprofessional approach to ensure safe and effective use. Structurally similar to epinephrine, isoproterenol increases heart rate and myocardial contractility while producing peripheral vasodilation and bronchodilation. Approved by the US Food and Drug Administration (FDA) in 1947, isoproterenol has both FDA-approved and off-label clinical applications.

This activity reviews the indications, mechanism of action, pharmacokinetics, dosing considerations, adverse effect profile, contraindications, and clinically significant drug interactions of isoproterenol. Given the drug’s potent cardiovascular effects and narrow therapeutic margin, its administration and monitoring require careful patient selection and close interprofessional collaboration. This activity is grounded in evidence-based medicine and is designed to improve overall patient care and clinical outcomes. In addition, this activity emphasizes the importance of interprofessional collaboration among healthcare providers in managing isoproterenol therapy and provides them with essential knowledge and practical tools for its optimal administration. By understanding the complex pharmacology of isoproterenol, healthcare professionals can optimize therapy by focusing on strategies to minimize adverse reactions while maximizing therapeutic effectiveness, aiming to deliver safe, effective, and individualized patient care, minimize adverse events, and improve patient outcomes.

Objectives:

• Identify FDA-labeled and evidence-supported off-label indications for isoproterenol in acute and perioperative care settings.
• Apply evidence-based dosing strategies and titration parameters for isoproterenol in adult and pediatric patients.
• Implement appropriate monitoring strategies, including electrocardiographic and hemodynamic surveillance, during isoproterenol administration.
• Collaborate with interprofessional healthcare teams to optimize isoproterenol therapy and reduce preventable medication-related complications.

Indications

Isoproterenol, also known as isoprenaline, is a nonselective beta-adrenoceptor agonist.[1] The drug is used to treat bradydysrhythmias and to evaluate electrophysiology in a supervised clinical setting. Structurally, the drug resembles epinephrine. Isoproterenol was first approved by the US Food and Drug Administration (FDA) for use in the United States in 1947. Both FDA-approved and off-label indications for isoproterenol are mentioned below.

FDA-Approved Indications

• Treatment of bronchospasm occurring during anesthesia (DailyMed, isoproterenol hydrochloride)
• Improvement of hemodynamic status in distributive shock and shock due to decreased cardiac output.

Previously FDA-approved indications include:

• Management of severe episodes of heart block and Adams-Stokes syndrome, except when caused by ventricular tachycardia or fibrillation
• Management of mild or transient episodes of heart block that do not require electric shock or pacemaker therapy
• Treatment of cardiac arrest from heart block when pacemaker therapy is unavailable (isoproterenol hydrochloride)

Off-label Uses

• Bradycardia [2]
• Cardiogenic shock
• Hypovolemic shock (adjunctive treatment) 
• Provocation of ventricular arrhythmias during electrophysiological studies to induce ventricular arrhythmias in patients with a history of arrhythmogenic right ventricular cardiomyopathy
• Torsades de pointes
• Beta-blocker overdose
• Ventricular arrhythmias secondary to atrioventricular (AV) block
• Short QT syndrome
• Electrical storm in patients with Brugada syndrome [3]
• Bradycardia in a cardiac transplant patient [4][5][6][7][8][9]
• Sotalol poisoning [10]
• Provocation of syncope during head-up tilt table testing in patients with suspected reflex syncope [11][12]
• Severe acute exacerbation of asthma in pediatric patients (inhalational use; not guideline supported) [13]
• Unmasking the latent arrhythmogenic triggers to verify the procedural success and durability of the atrial fibrillation ablation [14]

Mechanism of Action

Isoproterenol is a nonselective beta-1 and beta-2 adrenergic receptor agonist that produces the following effects: 

• Increased heart rate 
• Increased heart contractility 
• Relaxation of bronchial, gastrointestinal, and uterine smooth muscle 
• Peripheral vasodilation 

Both beta-1 and beta-2 adrenergic receptors exert their effects through a G-alpha stimulatory second messenger system. G-protein–coupled receptors are structurally composed of a 7-transmembrane-spanning protein. The extracellular domain serves as the ligand-binding site, whereas the intracellular domain links to a G-alpha stimulatory protein bound to a GDP molecule in the inactivated state.

Upon binding of the ligand to the extracellular domain of a beta-1 receptor, the G-alpha subunit exchanges a GDP molecule for a GTP and becomes activated. The activated G-alpha protein then dissociates from the intracellular domain and activates adenylate cyclase. Activated adenylate cyclase subsequently converts intracellular ATP into cyclic AMP (cAMP), which is the principal second messenger in this pathway.

cAMP activates protein kinase A (PKA), which phosphorylates L-type calcium channels in cardiac myocytes, resulting in increased intracellular calcium. PKA also causes an increase in calcium release from ryanodine receptors on the sarcoplasmic reticulum.

Beta-1 adrenergic receptors are primarily concentrated in cardiac tissues. The terminal effects of beta-1 adrenergic receptor activation are an increase in intracellular calcium. In cardiac pacemaker cells, increased calcium increases the slope of phase 4 of the cardiac pacemaker action potential. By increasing the slope of phase 4, pacemaker cells reach the threshold more rapidly, resulting in the characteristic increase in heart rate observed in patients receiving an isoproterenol infusion. In non-pacemaker cardiac myocytes, an increase in intracellular calcium causes the increased contractility characteristic of isoproterenol infusion.[15]

The result of beta-1 agonism on the heart can be summarized as follows:

• Positive inotropy (contractility)
• Positive lusitropy (relaxation)
• Positive chronotropy (heart rate)
• Positive dromotropy (conduction velocity) 

Beta-2 adrenergic receptors function similarly to beta-1 receptors. Activation of these G-protein–coupled receptors results in an increase in intracellular cAMP, which then activates PKA. PKA phosphorylates and inactivates myosin light chain kinase (MLCK). In smooth muscle cells, MLCK catalyzes myosin phosphorylation, leading to myosin-actin cross-bridge formation and muscle contraction. As stated, agonism of beta-2 receptors leads to inactivation of MLCK and subsequent relaxation of smooth muscle, bronchial dilation, peripheral vasodilation, and relaxation of gastrointestinal and uterine smooth muscle.[16]

Other effects of isoproterenol include:

• Hepatic glycogenolysis via beta-2 adrenergic receptor activation
• Release of glucagon from the pancreas via beta-2 adrenergic receptors
• Activation of the renin-angiotensin-aldosterone system in the kidney through beta-1 adrenergic receptor stimulation [17]

Pharmacokinetics (Adapted From the Label and PubChem )

Absorption: Isoproterenol becomes active immediately upon infusion. 

Distribution: Isoproterenol exhibits approximately 68.8% plasma protein binding. 

Metabolism: Isoproterenol undergoes hepatic metabolism mediated by the cytochrome P450 (CYP450) enzyme system and is also metabolized in other tissues by catechol-O-methyltransferase (COMT).[18] Conjugation in hepatic and pulmonary tissues is the primary metabolic pathway.

Excretion: The elimination half-life of intravenous isoproterenol ranges from 2.5 to 5 minutes. After 48 hours, approximately 12.2% to 27.0% of the drug is recovered in the feces and 59.1% to 106.8% in the urine.

Administration

Isoproterenol is administered intravenously via an infusion pump. Notably, adult intravenous infusion is expressed as micrograms per minute (mcg/min), whereas pediatric dosing is expressed in micrograms per kilogram per minute (mcg/kg/min).

Available Dosage Forms and Strengths

Brand and generic formulations: 0.2 mg/mL solution (1 mL and 5mL) 

Adult Dosage (FDA-Approved)

• Distributive shock and shock due to reduced cardiac output: For preparation, 5 mL (1 mg) of isoproterenol should be diluted in 500 mL of 5% dextrose injection. The recommended adult dose is administered as a continuous intravenous infusion at a rate of 0.5 to 5 mcg/min, which corresponds to 0.25 to 2.5 mL/min of the diluted solution. The infusion rate should be titrated according to heart rate, central venous pressure, blood pressure, and urine output. If the heart rate exceeds 110 beats per minute, dose reduction or temporary discontinuation of the infusion should be considered.

• Bronchospasm during anesthesia: For preparation, 1 mL (0.2 mg) of isoproterenol should be diluted with 10 mL of normal saline or 5% dextrose injection. The initial dose is 10 to 20 mcg, administered as an intravenous bolus, which corresponds to 0.5 to 1 mL of the diluted solution. Subsequent doses equal to the initial dose may be repeated as needed.

• Bradydysrhythmias and AV nodal block: Isoproterenol may be administered as a continuous infusion at a rate of 2 to 10 mcg/min, titrated to the desired clinical effect.[4] 

• Adam-Stokes attacks: For the management of Adams–Stokes attacks, isoproterenol is administered intravenously at a rate of 2 to 20 mcg/min. Therapy should be initiated at 5 mcg/min and adjusted based on clinical response.

Adult Dosage (Off-Label)

• Brugada syndrome: Isoproterenol may be administered as a bolus of 1 to 2 mcg, followed by a continuous infusion at 0.15 to 0.3 mcg/min for up to 24 hours.[9]

• Cardiogenic shock: Isoproterenol may be administered as a continuous infusion at a rate of 2 to 20 mcg/min, titrated to clinical response.[5]

• Provocation of syncope during tilt table testing: Isoproterenol may be initiated at 1 mcg/min and then increased based on the desired physiological response, to a maximum dose of 5 mcg/min.

• Provocation of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy: Isoproterenol may be administered at 45 mcg/min for 3 minutes, followed by rhythm evaluation.[6]

• Refractory torsades de pointes: Isoproterenol may be administered as a continuous infusion at 2 to 10 mcg/min, titrated to patient response.[8] 

Pediatric Dosage

• Bradycardia and AV nodal block: Isoproterenol may be administered as a continuous intravenous infusion at a rate of 0.05 to 0.5 mcg/kg/min, titrated to the desired clinical effect. The maximum recommended dose is 2 mcg/kg/min.[4] 

Neonatal Dosage

• Bradycardia: Isoproterenol may be administered as a continuous infusion at a rate of 0.05 to 1 mcg/kg/min, titrated to clinical effect.[19]

Specific Patient Populations

Hepatic impairment: No dosage adjustment for isoproterenol is specified in the product label for patients with hepatic impairment.

Renal impairment: No dosage adjustment for isoproterenol is specified in the product label for patients with renal impairment.

Pregnancy considerations: The use of isoproterenol during pregnancy has not been specifically evaluated. However, extensive clinical experience with isoproterenol in pregnant patients over several decades has not demonstrated an increased risk of major congenital disabilities, miscarriage, or adverse maternal or fetal outcomes.

Potential risks to both the mother and fetus exist when isoproterenol is administered during labor or delivery. Hypotension due to shock constitutes a medical emergency in pregnancy and may be fatal if not promptly treated. Delays in intervention for shock-related hypotension can increase maternal and fetal morbidity and mortality. Life-sustaining therapy should not be withheld from a pregnant patient because of concerns regarding the potential fetal effects of isoproterenol.

Isoproterenol inhibits spontaneous and oxytocin-induced uterine contractions and may prolong the second stage of labor. Accordingly, its use should be avoided during the second stage of labor. In obstetric practice, isoproterenol should also be avoided when maternal blood pressure exceeds 130/80 mm Hg.

Breastfeeding considerations: The presence of isoproterenol in human breast milk is presently unknown.[20] However, given its short elimination half-life, exposure to a breastfed infant is expected to be minimal.

Pediatric patients: The safety and efficacy of isoproterenol have not been established in pediatrics. Intravenous infusions of isoproterenol in refractory asthma at rates of 0.05 to 2.7 mcg/kg/min have been associated with clinical deterioration, myocardial necrosis, congestive heart failure, and mortality.[21] The risks of cardiac toxicity appear to be increased by acidosis, hypoxemia, and coadministration of corticosteroids, methylxanthines, theophylline, or aminophyllin, which are especially likely to be present in these patients.[22] If isoproterenol is used in pediatric patients with refractory asthma, close monitoring is necessary, including ongoing assessment of vital signs, regular electrocardiographic (ECG) monitoring, and measurement of cardiac enzyme levels.[13]

Older patients: In clinical trials of isoproterenol, the number of enrolled patients aged 65 or older was insufficient to determine whether responses differ from those observed in younger adults. Limited data suggest that healthy or hypertensive older adults are less responsive to beta-adrenergic stimulation than younger subjects. For geriatric patients, dosing should be approached cautiously, typically beginning at the lower end of the dosing range, due to the increased likelihood of reduced hepatic, renal, or cardiac function, as well as the presence of comorbid conditions and concomitant polypharmacy.

Adverse Effects

Adverse effects of isoproterenol may involve multiple organ systems, as mentioned below.

Common

• Headache
• Dizziness
• Upset stomach
• Flushing
• Fatigue
• Nervousness
• Diaphoresis
• Blurred vision
• Tachyarrhythmia
• Hypertension or hypotension

Cardiovascular

• Angina 
• Flushing 
• Hypotension 
• Hypertension 
• Palpitations 
• Ventricular arrhythmia 
• Premature ventricular contractions 
• Adams-stokes syndrome 
• Bradycardia (with tilt table testing) 
• Atrial fibrillation [23]

Respiratory 

• Dyspnea 
• Edema 

Ophthalmic 

• Blurred vision 

Central Nervous System

• Headache
• Dizziness
• Nervousness
• Restlessness
• Seizures 

Gastrointestinal

• Nausea
• Vomiting 

Endocrine and Metabolic

• Hypokalemia
• Increased serum glucose 

Musculoskeletal 

• Tremor
• Weakness 

Drug-Drug Interactions

Risk C: Monitoring therapy

• Atomoxetine: Concomitant use may increase heart rate.
• Cannabinoid-containing products: Concomitant use may increase heart rate.
• Catechol-O-methyltransferase inhibitors: Isoproterenol is degraded by COMT; concomitant use with COMT inhibitors may increase isoproterenol concentrations and the risk of adverse effects.
• Doxofylline: Concomitant use may increase the risk of doxofylline toxicity.
• Tedizolid: Concomitant use may increase the risk of hypertensive episodes.

Risk D: Considering modifying therapy

• Topical cocaine: Concomitant use increases the risk of hypertension, tachycardia, and increased oxygen demand.
• Linezolid: Concomitant use may increase the risk of hypertension due to the COMT inhibitor-like activity of linezolid.
• Mifepristone: Concomitant use may increase the risk of QTc prolongation.
• QTc-prolonging agents: Concomitant administration with other QTc-prolonging drugs should be avoided.
• Epinephrine: Both medications are direct stimulants, and their combined effects may precipitate severe arrhythmias when administered concurrently.
• Beta blockers: Beta-adrenergic blocking drugs, such as propranolol, may antagonize the cardiostimulating and bronchodilating effects of isoproterenol.

Risk X: Avoiding combination or using alternatives

• Inhaled anesthetics: Concomitant use may increase the risk of arrhythmias.
• Benzphetamine
• Clomipramine
• Diethylpropion
• Epinephrine
• Methamphetamine
• Midodrine
• Phendimetrazine
• Procarbazine
• Sotalol

Contraindications

Absolute contraindications include:

• Angina
• Tachydysrhythmias
• Preexisting ventricular arrhythmias
• Digoxin intoxication
• Sulfa allergy (formulations contain sulfites)

Isoproterenol should be used with caution in patients with conditions mentioned below.

• Cardiovascular disease: Isoproterenol increases myocardial oxygen demand.
• Diabetes: Isoproterenol may increase blood glucose levels.
• Distributive shock: Beta-2 adrenergic agonism may further decrease total peripheral resistance.
• Hyperthyroidism: Isoproterenol may induce a thyroid storm.
• Sulfite sensitivity: Formulations contain sulfites, which may provoke allergic reactions in susceptible patients.
• Older patient populations

Monitoring

Clinicians should monitor baseline and periodic electrolyte levels, blood pressure, and an ECG. Vital signs, including heart rate and respiratory rate, along with arterial blood gas analysis, blood glucose levels, and serum potassium and magnesium levels, require continuous monitoring in patients receiving isoproterenol.

Toxicity

Signs and Symptoms of Overdose

Acute toxicity from isoproterenol can cause a significant decrease in blood pressure. Accidental overdose is most commonly manifested by tachycardia or other arrhythmias, hypotension or hypertension, and angina. In such cases, the rate of isoproterenol administration should be reduced or the drug discontinued until the patient stabilizes. Continuous monitoring of pulse, respiratory rate, electrocardiography, and blood pressure is recommended.

Management of Overdose

No known antidote exists for isoproterenol toxicity, although investigational therapies are under study.[24] Management is primarily supportive. Recent animal research indicates that, in isoproterenol-induced heart failure, empagliflozin and sacubitril/valsartan might offer cardioprotective effects and could serve as potential treatment options. Nonetheless, definitive conclusions require larger, evidence-based studies in humans.[25]

Enhancing Healthcare Team Outcomes

Isoproterenol is most commonly prescribed by a cardiologist; however, its use requires close coordination among an interprofessional healthcare team. This team typically includes intensivists, cardiologists, cardiac surgeons, critical care specialists, pharmacists, and ICU nursing staff. Isoproterenol is administered exclusively as an intravenous infusion and is generally reserved for severe bradycardia, heart block, or cardiac arrest. In select circumstances, it may also be used to manage hypovolemic shock or bronchospasm. Due to its potent beta-adrenergic effects, isoproterenol can precipitate tachyarrhythmias and hypertension, particularly at higher doses. When administered in the ICU setting, continuous hemodynamic and electrocardiographic monitoring is required for patients. With the widespread availability of pacemakers and alternative chronotropic agents, the clinical use of isoproterenol has declined in the current medical paradigm.[26]

Effective and safe use of isoproterenol depends on interprofessional collaboration among healthcare providers. While the ordering clinician determines the indication and initiates therapy, optimal management requires active involvement from the entire care team. Pharmacists play a critical role in verifying dosing, preparing infusions, and conducting thorough medication reconciliation. Consultation with a board-certified cardiology pharmacist is particularly valuable, given their expertise in cardiovascular pharmacotherapy, drug interactions, dose adjustments, and monitoring for adverse effects.

Nursing staff are on the front line of obtaining accurate medication histories and performing the ongoing monitoring required during isoproterenol administration. Any abnormal findings or clinical concerns should be promptly communicated to the healthcare team, including prescribing clinicians and pharmacists, to allow timely dose adjustments or therapy modifications. This level of coordination is essential given the severity of the conditions treated with isoproterenol and the potential for significant adverse effects or drug interactions. Nursing staff with specialized training in cardiology or critical care can provide additional clinical insight and enhance patient safety. Effective, collaborative interprofessional communication is essential to optimize isoproterenol therapy, improve clinical outcomes, and minimize adverse events.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Noguchi K, Nagai A, Kashimoto N, Kobayashi R, Okawa K, Shinkuma M, Inoue R, Kanae H, Matsushita M, Ueda C. Possible Involvement of β₁-Adrenoceptors in the Positive Chronotropic Effects of Mirabegron. Biol Pharm Bull. 2026;49(1):47-56. [PubMed: 41500611]

2.

Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, Goldschlager NF, Hamilton RM, Joglar JA, Kim RJ, Lee R, Marine JE, McLeod CJ, Oken KR, Patton KK, Pellegrini CN, Selzman KA, Thompson A, Varosy PD. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019 Aug 20;140(8):e382-e482. [PubMed: 30586772]

3.

El-Battrawy I, Roterberg G, Kowitz J, Aweimer A, Lang S, Mügge A, Zhou X, Akin I. Incidence, recurrence and management of electrical storm in Brugada syndrome. Front Cardiovasc Med. 2022;9:981715. [PMC free article: PMC9640734] [PubMed: 36386327]

4.

Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW, Kudenchuk PJ, Ornato JP, McNally B, Silvers SM, Passman RS, White RD, Hess EP, Tang W, Davis D, Sinz E, Morrison LJ. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010 Nov 02;122(18 Suppl 3):S729-67. [PubMed: 20956224]

5.

van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, Menon V, Ohman EM, Sweitzer NK, Thiele H, Washam JB, Cohen MG., American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation. 2017 Oct 17;136(16):e232-e268. [PubMed: 28923988]

6.

Denis A, Sacher F, Derval N, Lim HS, Cochet H, Shah AJ, Daly M, Pillois X, Ramoul K, Komatsu Y, Zemmoura A, Amraoui S, Ritter P, Ploux S, Bordachar P, Hocini M, Jaïs P, Haïssaguerre M. Diagnostic value of isoproterenol testing in arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2014 Aug;7(4):590-7. [PubMed: 24970294]

7.

Benditt DG, Ferguson DW, Grubb BP, Kapoor WN, Kugler J, Lerman BB, Maloney JD, Raviele A, Ross B, Sutton R, Wolk MJ, Wood DL. Tilt table testing for assessing syncope. American College of Cardiology. J Am Coll Cardiol. 1996 Jul;28(1):263-75. [PubMed: 8752825]

8.

Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e272-e391. [PubMed: 29084731]

9.

Watanabe A, Fukushima Kusano K, Morita H, Miura D, Sumida W, Hiramatsu S, Banba K, Nishii N, Nagase S, Nakamura K, Sakuragi S, Ohe T. Low-dose isoproterenol for repetitive ventricular arrhythmia in patients with Brugada syndrome. Eur Heart J. 2006 Jul;27(13):1579-83. [PubMed: 16760208]

10.

Cole JB, Kunzler NM, Jurao AR, Fuchs RT, Olives TD, Wilkinson JL. Sotalol poisoning and its unique treatment considerations compared with traditional therapies for beta-adrenoceptor blocking drug poisoning. Clin Toxicol (Phila). 2025 Mar;63(3):217-220. [PubMed: 39882937]

11.

Guida P, Troisi F, Di Monaco A, Romanazzi G, Iacoviello M, Grimaldi M. Head-up tilt testing in patients with suspected vasovagal syncope: A meta-regression modelling. Int J Cardiol. 2026 Jan 01;442:133908. [PubMed: 40976356]

12.

de Ruiter SC, van Marum RJ, Ruiter JH, Hemels MEW, de Groot JR, Jansen RWMM. Head-up tilt testing in older syncope patients: a systematic review. Age Ageing. 2025 Mar 28;54(4) [PMC free article: PMC11982670] [PubMed: 40207380]

13.

Katsunuma T, Fujisawa T, Maekawa T, Akashi K, Ohya Y, Adachi Y, Hashimoto K, Mizuno M, Imai T, Oba MS, Sako M, Ohashi Y, Nakamura H. Low-dose l-isoproterenol versus salbutamol in hospitalized pediatric patients with severe acute exacerbation of asthma: A double-blind, randomized controlled trial. Allergol Int. 2019 Jul;68(3):335-341. [PubMed: 30846304]

14.

Mohanty S, Casella M, Doty B, Schiavone M, Gabrah K, Valeri Y, Torlapati PG, La Fazia VM, Gianni C, Al-Ahmad A, Burkhardt JD, Gallinghouse GJ, Horton R, Allison J, Bode W, Sharma R, Dello Russo A, Tondo C, Nair DG, Natale A. Ensuring catheter-tissue contact with intracardiac echocardiography during pulsed-field ablation improves procedure outcome in patients with atrial fibrillation. Heart Rhythm. 2025 Oct;22(10):e875-e881. [PubMed: 40414261]

15.

Desimine VL, McCrink KA, Parker BM, Wertz SL, Maning J, Lymperopoulos A. Biased Agonism/Antagonism of Cardiovascular GPCRs for Heart Failure Therapy. Int Rev Cell Mol Biol. 2018;339:41-61. [PubMed: 29776604]

16.

Matera MG, Page C, Rinaldi B. β2-Adrenoceptor signalling bias in asthma and COPD and the potential impact on the comorbidities associated with these diseases. Curr Opin Pharmacol. 2018 Jun;40:142-146. [PubMed: 29763833]

17.

Biazi GR, Frasson IG, Miksza DR, de Morais H, de Fatima Silva F, Bertolini GL, de Souza HM. Decreased hepatic response to glucagon, adrenergic agonists, and cAMP in glycogenolysis, gluconeogenesis, and glycolysis in tumor-bearing rats. J Cell Biochem. 2018 Sep;119(9):7300-7309. [PubMed: 29761924]

18.

Bonifácio MJ, Palma PN, Almeida L, Soares-da-Silva P. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev. 2007 Fall;13(3):352-79. [PMC free article: PMC6494163] [PubMed: 17894650]

19.

Matsubara S, Morimatsu Y, Shiraishi H, Kuwata T, Ohkuchi A, Izumi A, Takeda S, Suzuki M. Fetus with heart failure due to congenital atrioventricular block treated by maternally administered ritodrine. Arch Gynecol Obstet. 2008 Jul;278(1):85-8. [PubMed: 18066569]

20.

Mahon WA, Reid DW, Day RA. The in vivo effects of beta adrenergic stimulation and blockade on the human uterus at term. J Pharmacol Exp Ther. 1967 Apr;156(1):178-85. [PubMed: 6023594]

21.

Yassaghi Y, Jeddi S, Kashfi K, Ghasemi A. Myocardial infarct size is reduced by nitrite and nitrate administration: a systematic review and meta-analysis of animal studies. EXCLI J. 2024;23:18-33. [PMC free article: PMC10864704] [PubMed: 38357094]

22.

Hasebe H, Yoshida K, Furuyashiki Y, Nogami A, Ieda M. Oral caffeine intake amplifies the effect of isoproterenol in patients with frequent premature ventricular contractions. Europace. 2020 Aug 01;22(8):1261-1269. [PubMed: 32500131]

23.

Tutuianu C, Pap R, Riesz T, Bencsik G, Makai A, Saghy L. Is adenosine useful for the identification of atrial fibrillation triggers? J Cardiovasc Electrophysiol. 2019 Feb;30(2):171-177. [PubMed: 30375070]

24.

Shackebaei D, Hesari M, Ramezani-Aliakbari S, Hoseinkhani Z, Ramezani-Aliakbari F. Gallic acid protects against isoproterenol-induced cardiotoxicity in rats. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271211064532. [PubMed: 35193428]

25.

Muric M, Srejovic I, Novakovic J, Zivkovic V, Jovic JJ, Sretenovic J, Nikolic M, Lazarevic N, Andjic M, Kocovic A, Uzelac JJ, Bolevich S, Jakovljevic V. The Combined Empagliflozin and Sacubitril/Valsartan Therapy Attenuates Isoproterenol-Induced Heart Failure in Rats: Functional, Molecular, and Structural Insights. Cardiovasc Drugs Ther. 2026 Feb;40(1):81-95. [PubMed: 39913081]

26.

Kislitsina ON, Rich JD, Wilcox JE, Pham DT, Churyla A, Vorovich EB, Ghafourian K, Yancy CW. Shock - Classification and Pathophysiological Principles of Therapeutics. Curr Cardiol Rev. 2019;15(2):102-113. [PMC free article: PMC6520577] [PubMed: 30543176]

Disclosure: Michael Szymanski declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Davinder Singh declares no relevant financial relationships with ineligible companies.